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Abstract: Motor neurone disease is a progressive disease, and the patient and his/her family 
face many challenges during the disease progression, with increasing weakness and multiple 
losses of function. The provision of care for these patients and their families is equally chal-
lenging, anticipating and responding to the person’s needs. There are increasing challenges as 
more is understood about the disease and its management, including the genetic basis, cognitive 
change, the use of interventions such as ventilatory support, and gastrostomy. There is also an 
increasing need to ensure that the later stages are recognized so that all can be more prepared 
for the end of life, including recognition of deterioration and end of life, advance care planning, 
symptom management and psychosocial care at the end of life, and coping with requests for 
assisted dying. Careful assessment and good multidisciplinary team (MDT) work can enable 
patients and their families to have as good a quality of life as possible, and allow a peaceful 
death of the patient.
Keywords: Amyotrophic lateral sclerosis, end of life care, cognitive change, noninvasive ven-
tilation, gastrostomy, advance care planning
Introduction
Patients with motor neurone disease (MND) and their families face many challenges, 
along with multidisciplinary teams caring for them. MND is a progressive disease, 
the etiology of which is usually unknown, although there is increasing evidence of a 
genetic component.1 There is progressive loss of neurones – both motor neurones and 
within the brain – leading to progressive muscle loss and dysfunction. This is very 
individualized and varies from person to person but may present as follows:
•	 Amyotrophic lateral sclerosis, with both upper and lower motor neurone loss, 
 leading to a mixed pattern of weakness, spasticity, and wasting. This is the com-
monest form of the disease, affecting ∼66% of patients at diagnosis.
•	 Progressive bulbar palsy, affecting ∼20% of patients at diagnosis, with the bulbar area 
being primarily affected initially, leading to speech and swallowing problems.
•	 Progressive muscular atrophy, affecting only 10% of patients, with primarily lower 
motor neurone damage, leading to weakness of arms or legs, affecting more com-
monly men in their 50s and with a slower progression and a longer prognosis of 
up to 10 years.2
•	 Rarely, MND may present as a respiratory failure due to respiratory muscle and 
diaphragmatic weakness. The diagnosis of MND may be made after the start of 
respiratory support.3
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•	 MND may present as frontotemporal dementia (FTD) 
with the cognitive changes presenting before the physical 
changes of MND; dementia may occur in up to 15% of 
all patients.
At present, there is no curative treatment, although rilu-
zole has been shown to extend life by a few months.4 More 
recent evidence shows that MDT support5–7 and noninvasive 
ventilation (NIV)8 will extend life. The prognosis is often 
2–3 years, although 25% live for 5 years and 10% will be 
alive at 10 years.2 As there is no curative treatment, palliative 
care can be considered as appropriate at the time of diagnosis, 
which can be defined as follows: “An approach that improves 
the quality of life of patients and their families facing prob-
lems associated with life-threatening illness, through the 
prevention and relief of suffering, early identification and 
impeccable assessment and treatment of pain and other 
problems, physical, psychosocial and spiritual.”9
There is increasing awareness of the role of palliative 
care in MND, and the European Guidelines on MND care10 
and the American Practice Parameters11 press for improved 
care throughout the disease progression and at the end of 
life. A recent Consensus Document from the European 
Association for Palliative Care and the European Academy 
of Neurology has also stressed the role of palliative care for 
all neurological diseases.12
Moreover, there is increasing evidence that palliative care 
is effective in improving quality of life. A study of patients 
with neurological diseases showed that there was improve-
ment in overall quality of life and in the symptoms of patients 
with MND, multiple sclerosis, and Parkinson’s disease.13 This 
has been supported by other studies with multiple sclerosis 
and other neurological diseases where symptoms and quality 
of life are seen to improve with a palliative care approach.14,15 
However, there are increasing challenges with the provision 
of palliative care for people with MND, as there is increasing 
recognition of certain aspects of the disease progression – 
genetics, cognitive change, respiratory dysfunction, new 
interventions in management (gastrostomy, respiratory sup-
port), issues toward the end of life, recognition of the end of 
life, advance care planning, care at the end of life, requests 
for assisted dying, and the increasing complexity of multiple 
team involvement. The aim of this review is to summarize 
some of these issues and look ahead into the future.
The role of genetics
Over the last 20 years, the role of genetics in the etiology 
of MND has been recognized. Although 5%–10% of people 
with MND have a clear family history, until recently, it was 
possible to identify gene mutations in only a small minority. 
However, there are now more than 15 genes recognized, many 
with multiple mutations, and recently, it has been shown 
that in people with familial MND, a gene abnormality can 
be found in 60% – most commonly the C9orf72 gene (often 
with associated FTD, or some family members may only 
have FTD), and also the SOD1, TDP, and FUS.2 Moreover, 
within the population with no family history, ie, “sporadic” 
MND, there is evidence of gene mutations, particularly 
C9orf72.2 It would seem that there may be complex genetic 
and environmental factors involved in MND, with much 
still to learn.1
Thus, there is a new challenge that people with MND, 
whether they have a family history, or not may request gene 
testing. This has great implications for patients and their 
families. The majority of gene mutations show autosomal 
dominance, although the penetrance of the gene mutation 
is not always clear, so not all carriers of the gene mutation 
may develop the disease. The identification of people with 
abnormal genes, and thus with a very high risk of developing 
MND, will have many implications for families and indi-
viduals. There may be decisions taken not to have children, 
or to consider alternative complex in vitro fertilization and 
reimplantation of unaffected zygotes. There may also be 
complex psychosocial reactions and family interactions after 
the genetic basis of the disease has been identified.
Although a gene mutation may be identified in ∼50%–60% 
of patients with familial MND, it may not be possible to iden-
tify any abnormal gene mutation at the present time. Thus, 
this leaves further uncertainty and unresolved issues for all 
involved. Consideration of genetic testing is complex and 
should be taken after careful consideration and discussion 
with experienced genetic services.
Cognitive change
There have been similar developments in the awareness of 
cognitive change in MND over the last 20 years. Although 
dementia was originally described in the early descriptions 
of MND, it was always stated that there was no evidence of 
brain changes. However, in the last 20 years, there has been 
increasing evidence of cognitive and behavioral change, and 
several forms can be identified:
ALSci – cognitive impairment 28%;
ALSbi -– behavioral impairment 39%;
ALS–FTD – frontotemporal dementia 15%.16
These changes can have a large influence on the care 
and quality of life of both the patient and family carers. The 
behavioral changes can be very hard for families and carers, 
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as there are issues of safety and decision making. Although 
FTD may be more obvious and have a major influence on 
the care provided and the ability of family carers to cope 
at home, the less pronounced frontal changes can greatly 
influence decision making and forward planning. These may 
affect day-to-day care, and help may be needed for all carers, 
family, and professionals to ensure that any discussions and 
decision making is kept as simple as possible – for instance, 
presenting a range of options may be too complex and it may 
be necessary to have a simple decision between two clear 
options to facilitate the patient’s involvement.16
This awareness is increasing, and there are new assess-
ment tools to allow professionals to recognize cognitive 
change.17,18 These often include both patient and family 
carers, who may recognize earlier changes in behavior. The 
Edinburgh Cognitive Assessment Scale includes all involved 
and can be helpful in identifying cognitive changes, although 
there is complexity in analyzing the results and assessing how 
relevant these changes are in the day-to-day care of patients.17 
The ALS-Cognitive Behavioral Screen has also been used to 
help assess cognitive function.18 The recognition of possible 
change may be helpful in ensuring that advance care plan-
ning is undertaken earlier in the disease progression while 
the patient can express his or her views clearly.
If patients are to be included in decision making, it may 
be necessary to consider advance care planning, such as an 
advance directive or the definition of a proxy for decision 
making, to ensure that their wishes are known and can be 
respected. This is now a clearer challenge, as the patient may 
be facing increasing cognitive change, as well as increasing 
problems with communication.16
Interventions
There are now interventions that may improve either the 
quality of life and/or prognosis, including gastrostomy for the 
continuation of feeding when someone cannot swallow effec-
tively, or NIV or invasive ventilation, with a tracheostomy, 
for respiratory failure due to diaphragmatic and respiratory 
muscle weakness. These do present further challenges in the 
assessment and recognition of the need for intervention, the 
issues of discussion about the benefits and problems, and the 
consideration of withdrawal at the end of life.19
Gastrostomy
Gastrostomy has been used to help people with swallowing 
and nutrition issues for many years.20 For people with MND, 
there is evidence that gastrostomy may improve quality of 
life and reduce stress on patients, families, and  professionals 
in the administration of fluid and medication, even at the 
end of life, but there is little convincing evidence that there 
is increased survival with gastrostomy.21 Moreover, there is 
some limited evidence that, if the patient has compromised 
respiratory function, there may be increased mortality and 
morbidity.11
The discussion of gastrostomy – either as percutaneous 
endoscopic gastrostomy (PEG) or percutaneous radiologically 
inserted gastrostomy (PRG or RIG) – can be complex.20,21 
It has been suggested that a gastrostomy should be considered 
if there is a 10% loss of weight, although even a 5% loss has 
been recently shown to have increased mortality.22 It is also 
helpful to start discussion when there are signs of swallow-
ing problems, as the discussion should be considered as a 
process over several weeks or months, rather than a sudden 
decision based just on weight loss.20 However, patients, and 
often their families, find discussion of interventions difficult 
and may put off decisions. As the decision is influenced as 
much by respiratory muscle function – if the forced vital 
capacity is ,50%, the mortality rises for the insertion of a 
PEG11 – the patient may not see a need for PEG and put off 
decisions until it is no longer possible as sedation is neces-
sary for a PEG and the risk increases greatly. It may still be 
possible to consider a PRG, as this is inserted using X-ray 
monitoring and the patient can remain more upright and 
even use the NIV.
The use of gastrostomy as the person deteriorates may 
also be complex. Families and carers may wish to continue 
a full nutritional feeding regime, even though this may no 
 longer be appropriate. However, for most patients,  the gas-
trostomy is used less as the disease progresses and can be 
used just to maintain hydration and the administration of 
medication even near to the end of life.20
Ventilatory support
The cause of death in the majority of patients with MND 
is respiratory failure. There is increasing evidence that 
the  recognition of early respiratory failure can allow 
 consideration of respiratory support, usually NIV, which 
may improve the quality of life and extend survival.8 There 
is a challenge to ensure that respiratory function is regularly 
assessed –  asking for symptoms, in particular orthopnea, 
poor interrupted sleep, morning headache, increased 
 dreaming or nightmares, lethargy, anorexia, breathlessness – 
and checking respiratory function and blood gases – using 
sniff nasal inspiratory pressure, measurement of forced 
vital  capacity, and checking oximetry, at rest or overnight 
if there is  suspicion of nocturnal respiratory insufficiency. 
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There are guidelines suggesting assessment regimes,23 but 
it may be a challenge to help patients and families see the 
importance and significance of regular supervision and 
testing. Moreover, it has been suggested that throughout the 
disease progression, even from diagnosis, there is the need 
to explain the reasoning behind the monitoring of respira-
tory function.23,24
The majority of patients will cope well with NIV, but some 
find it particularly difficult – if there are bulbar symptoms 
with drooling into the mask – or some people with feelings of 
claustrophobia.25 With perseverance, many can continue with 
NIV, but for those for whom it is too difficult, other ways of 
helping the symptoms – such as raising the head of the bed 
and helping the patient to be less supine, or opioids, such as 
oral morphine, to reduce the sensation of dyspnea.26,27
Symptoms are often managed very effectively by NIV, 
with improved sleep, reduced fatigue, and improved appetite. 
Survival may be increased, and the one trial of NIV showed a 
survival advantage of over 200 days – from 11 days without 
NIV to 216 days for the people tolerating NIV.8 However, 
there will be disease progression and many patients find 
this deterioration difficult, as they face increasing disability 
and dependency and often increasing speech and swallow-
ing issues.24 Although most patients require the NIV only to 
support breathing at night initially, as the disease progresses 
there is often the need to use NIV in the day, and some patients 
become dependent on continuous respiratory support, with 
severe breathlessness when they are not receiving NIV. 
Thus, many patients may feel that the burdens of continuing 
NIV are too great and they may wish to withdraw from this 
treatment. Although this decision may be taken by anyone 
who has the capacity to do so and is acting autonomously, 
there may be many issues raised – for patient, family, and 
professional carers.
The withdrawal of NIV may be seen as a challenge in the 
care of patients with MND. A survey of palliative medicine 
specialists showed that the process and discussion of with-
drawal of NIV was a source of ethical debate, emotional 
stress, and team stress,28 particularly as it was not a common 
event within their practice. Other studies of doctors and 
professionals and families have shown that there are often 
many debates and discussions of the ethics and practicalities 
of withdrawal – with concerns that withdrawal would be seen 
as assisting suicide/dying or even euthanasia.28,29 However, 
the ethical position can be seen to be clear if a patient with 
capacity makes the autonomous decision to refuse a treat-
ment, which he or she feels is burdensome, or there is actually 
an imperative to ensure that this occurs.30
In many cases, there may be doubts and conflicts with the 
patient, family, and the professional team.28,29 As a patient 
deteriorates, the assessment of capacity may be more  complex 
and, as communication becomes more difficult, these discus-
sions can be challenging. On occasions, patients may have 
made their wishes clear with an advance directive stating 
that they do not wish to continue with NIV in certain cir-
cumstances. Even then, it may be complex assessing whether 
the person has reached the situation that they envisaged and 
there may be a lack of clarity in such advance directives.30 
Moreover, there are often disagreements within families 
and the caring professional teams, as everyone has his or 
her own particular ethical standpoint, the understanding of 
which may be inaccurate and not reflect the true ethical and 
legal aspects.
There are now clearer guidelines on the withdrawal of 
NIV,31 and these stress the need for clear communication 
with patient, family, and all the team involved, a clear plan 
for withdrawal – what medication to give to ensure that 
distress is minimized, who will give medication, who will 
remove the mask, and who will support the family – and 
with a clear ethical and legal explanation. If a patient is 
completely dependent on NIV, he or she will need to have 
medication to prevent distress, as the patient is very likely 
to become very breathless when NIV is reduced or removed. 
If a patient is not totally dependent on NIV, it may be pos-
sible to give medication if there is distress, although some 
anticipatory medication may be helpful to cope with the 
anxiety of patient, family, and professionals. Usually, an 
opioid, such as morphine or diamorphine, a benzodiazepine, 
such as midazolam, and an antimuscarinic, such as hyoscine 
hydrobromide or glycopyrronium bromide, is given, as a 
continuous subcutaneous infusion, with extra medication 
available to give intravenously or subcutaneously if there is 
distress with the procedure.31
With careful planning and discussion with all involved, 
NIV may be withdrawn without distress for the patient. 
However, there is a need for discussion of these issues of 
NIV to be undertaken before there is disease progression 
and dependency on NIV. It has been suggested that the 
discussion of disease progression and the management of 
dependency – using medication to reduce distress rather 
than NIV – should be undertaken at the time NIV is started 
and at regular intervals as the disease progresses.23,24 In 
this way, all can become aware of the issues, and advance 
care planning can be instigated, so that the patient’s wishes 
are known even if communication, cognition, or capacity 
becomes compromised.
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Tracheostomy ventilation may be possible and has 
been shown to extend life further, even for many years or 
decades.24,32 However, disease progression may lead to a 
patient becoming totally locked in with no way of commu-
nication.24 In the UK, tracheostomy is rarely performed as 
a planned procedure, although some patients, who present 
with acute respiratory failure, may receive a tracheostomy 
and start on ventilation before the diagnosis of MND is 
made. In other countries, tracheostomy is used more com-
monly, and in Japan up to 33% of all MND patients have 
full ventilation with tracheostomy.32 There are many ethical 
issues raised with the continued ventilation for a patient 
when he or she cannot communicate, and great care is 
needed in discussing these options. Studies have shown 
that Japanese neurologists would be less likely to have a 
tracheostomy if they developed MND, although this is often 
offered to their patients.33
Recognition of the end of life
A patient with MND is facing a short prognosis and usually 
dies from respiratory failure, often associated with a respira-
tory infection. This may follow a slow decline but may be a 
sudden decline over only a few days.34 The recognition that 
the patient is now at the end of life may be a challenge, par-
ticularly as the patient, family, and professionals may all see 
the gradual deterioration and not notice the final changes that 
may herald the end of life. It has been suggested that there 
are certain triggers that may be used to recognize this phase. 
For all neurological patients, these are the following:
•	 swallowing problems;
•	 recurring infection;
•	 marked decline in functional status;
•	 first episode of aspiration pneumonia;
•	 cognitive difficulties;
•	 weight loss;
•	 significant complex symptoms.35
For patients with MND, there may also be
•	 respiratory failure or increased breathlessness;
•	 reduced mobility;
•	 dysphagia.35
These triggers have been initially assessed, and a group of 
neurological patients were found to have an increased number 
of triggers as death approached, and aspiration pneumonia 
was particularly significant, and was often within 6 months 
of death.36
The importance of the recognition of the end-of-life 
phase may be in allowing the preparation of the patient, and 
often, more importantly, the family and carers, that time is 
limited, and in preparation for the dying phase. This may 
include the provision of anticipatory medication – morphine, 
 midazolam, and glycopyrronium bromide injections, and/or 
buccal  midazolam or sublingual lorazepam – that could be 
given if there is a sudden deterioration or development of 
breathlessness, pain, or distress. This has been developed 
within the “Just in case kit” by the MND Association in 
England,37 and has been supported for patients at the end of 
life by NICE.38 Careful discussion about the wishes of the 
patient and family – of place of death, funeral arrangements, 
will, and care at the end of life – may be important so that 
all are prepared as much as possible.18,30
Before the last stages of life, there is a need to consider 
planning ahead – advance care planning. This may be of 
particular importance in MND, and there is a challenge in 
enabling these discussions when the patient is still able to 
communicate and has not developed cognitive change.30 
Thus, discussion of wishes, including will, funeral, place 
of death, resuscitation, and use of invasive procedures such 
as gastrostomy, NIV, or even tracheostomy, will allow the 
patients to express their wishes and enable the family and 
professional carers to follow their wishes, even if they are 
no longer able to communicate them.30
Advance care planning may be ensuring that the wishes 
are clearly known, but there are specific ways to express these 
views such as the following:
•	 Advance directive (in England an Advance Decision to 
Refuse Treatment), which may record measures a patient 
does not wish at the end of life, such as resuscitation or 
ventilation. This may be a legally binding document if 
correctly completed and specific in its wording.
•	 Advance statement – a nonspecific document express-
ing the general wishes of a person, such as their wish 
not to have life extended if they are no longer able to 
communicate.
•	 The appointment of a proxy – who would be able to 
make decisions on the person’s behalf if he or she has 
lost capacity. In England, this Power of Attorney can be 
for property or health issues.
•	 A will that allows the person to clearly state his or her 
wishes for the belongings and monies.30
The discussion of these issues may be complex and 
difficult, especially because on occasions there may be an 
imperative to discussing and completing these documents 
if the person has reduced communication or has increasing 
cognitive change. However, with careful communication it is 
usually possible to raise these issues and ensure that patients 
are able to express their wishes and their autonomy, so that 
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if they do lose the capacity to make or express their views, 
these are still clearly known and can be acted on.18,30
Care of the dying
When death is expected, there is an even greater need to 
ensure that symptoms are managed effectively, especially 
pain, breathlessness, and fear. Careful assessment is essential, 
and consideration of all aspects of care, including psycho-
logical, social, and spiritual issues. If a patient is frightened 
about death, this may be the process of dying – fearing 
breathlessness or distress – or fear of death itself, as a deeper 
spiritual fear.39,40 Both these issues need to be addressed 
appropriately, and may include other members of the wider 
MDT, including a spiritual care adviser or priest/spiritual 
leader.40 As someone becomes more ill, the oral route for 
medication may become more difficult. If the patient has 
undergone gastrostomy, this may be used to administer 
medication until near to death. For many patients, parenteral 
medication may be necessary, using subcutaneous injec-
tions or a continuous subcutaneous infusion using a syringe 
driver.41 It is essential to continue opioid medication until 
death because, although a patient may become unrousable, 
he or she may still perceive pain or dyspnea and need to have 
appropriate medication.
There is also the need to support family and carers,39 and 
often professional carers who may have known the patient 
for some time. It is important that all involved in the patient’s 
care are aware that death is near and expected, so that they 
all act appropriately and support the patient, family, and 
each other.39,40
Assisted dying
Patients with MND often fear a distressing death, and the 
media often discuss the distress of dying with MND,  talking 
of breathlessness, pain, and loss of control. This has led 
many people to consider an assisted death – according to 
their country of residence. This may be assisted suicide – 
when the doctor provides medication for them to take with 
the explicit aim of ending life – or euthanasia – when a 
patient is given an injection of medication with the aim 
of ending life.42 This may be possible in the Netherlands 
(euthanasia and assisted suicide), Belgium (euthanasia), 
Luxembourg (euthanasia and assisted suicide), Switzerland 
(assisted suicide), Columbia (euthanasia) and several states 
in the US (assisted suicide).43 Patients with MND are often 
one of the patient groups more likely to ask for an assisted 
death – 22% of patients in the Netherlands received eutha-
nasia and 10% terminal sedation.44
Thus, there is increased awareness of the issues of assisted 
dying, and there has been pressure across the world for 
increased access to assisted dying, often using a person with 
MND as an example of why this should be allowed – often 
exaggerating the fears of dying and of distress.41 The evidence 
from many studies is that death from MND is peaceful when 
there is good palliative care – with good management of 
both symptoms and the support of patient and family.34,45 For 
many people, this information can be reassuring and reduce 
the wish for an assisted death, but a small minority may 
still wish to keep control and wish to choose their mode of 
dying. Within countries where there is no legislation allowing 
assisted dying, there will be the need to explain the position 
clearly and stress that actions can be taken to ensure that 
life is not unnecessarily prolonged – as many people fear 
prolongation by unnecessary intervention – and advance 
care planning can allow their wishes to be known and for 
these to be respected even if they are not able to communicate 
or have lost capacity to express their wishes.30 A “Do Not 
Attempt Cardiopulmonary Resuscitation” (DNACPR) order 
can also be helpful in showing that a natural death would be 
allowed, and the provision of anticipatory medication shows 
that if there are difficult or distressing symptoms, these will 
be managed effectively and speedily.30,41 Some patients may 
still request assisted dying and may even seek this in another 
country – for instance, traveling to Switzerland and receiving 
an assisted suicide at Dignitas.
Team issues
The management of a person with MND will often need the 
involvement of an MDT, and this has been suggested as the 
aim in the provision of care.5–7 Moreover, there is evidence 
that the MDT approach improves both quality of life and 
the length of survival – one study suggesting that the 1-year 
mortality was decreased by 29.7%5 and another suggesting 
that the median survival was 19 months for the MDT group 
compared to 11 months for standard care6 and a further study 
showing a survival difference.7
However, there may also be other issues arising within 
any MDT – as there may be differences of opinion or even 
conflicts between team members. This has been highlighted 
in the issues of withdrawal of NIV, as there were often differ-
ent understanding of the ethical issues – as one consultant in 
palliative medicine talked of “walking onto the ward at the 
allocated time and being treated like an executioner is not 
easy” and another spoke of the “nurses need emotional and 
ethical support.”28 These issues may take time and careful 
discussion, and one of the main roles of the MDT meeting 
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may be to allow these discussions and the support of the 
team.
These issues may be even greater when several teams are 
involved in the patient’s care. It may not be unusual for other 
teams – respiratory teams looking at NIV,  gastroenterology 
considering PEG, neurology team, specialist palliative 
care, primary care. All of these teams may have different 
standpoints, with different ways of working, varying ethical 
systems, and ways of working as a team.46 These issues can 
lead to conflict between teams and understanding the differ-
ent ways of working, and the differing pressures and stresses 
on team members and team dynamics are important if the 
care of the patient and family is not to be compromised. As 
the care of the patient with MND becomes more complex – 
perhaps with psychological services assessing cognition, 
genetic counseling services providing advice – the need of 
a clear lead is important. An MDT should define, if at all 
possible, a key contact – although a single team contact is 
often suggested, a “team contact” may be more realistic to 
cover leave and sickness absences of a single person.46 The 
MDT should ensure that there is clear coordination and the 
contact(s) are able to liaise with other teams and provide a 
clear pathway for the patient and family.46
Conclusion
The care of a patient with MND, and their family, is becom-
ing more complex as further information about the disease 
and its effects are found and further interventions are used to 
improve the quality and length of life. Careful coordination 
is essential, and the MDT needs to be there to help patient 
and family meet all these challenges.
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